158 results
Page 4 of 8
8-K
EX-99.1
2liu wx2ai0ve
30 Nov 21
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer
9:33am
8-K
EX-99.1
g64a58l3 ch5
12 Nov 21
Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share
9:00am
8-K
EX-99.1
c7w w82q1
3 Nov 21
Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors
4:38pm
8-K
EX-99.1
7qgtj7
22 Oct 21
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain
9:00am
8-K
EX-99.1
4nxw7xp
31 Aug 21
Adial Pharmaceuticals Exceeds Enrollment Target In Onward™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
10:39am
8-K
EX-99.1
0kmarxftvk3z
5 Aug 21
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
10:21am
424B3
x7k llmi9c9j
30 Jul 21
Prospectus supplement
5:11pm
8-K
EX-99.1
4ge4846r
16 Jul 21
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
9:20am
8-K
EX-99.1
at89jo5
9 Jul 21
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
iuj4m8vn4p
6 Jul 21
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
10:35am
8-K
EX-99.1
cw18zis
25 Jun 21
Adial Pharmaceuticals Provides Regulatory and Development Update
12:00am
8-K
EX-99.1
1b6ybo77bda
22 Jun 21
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test
9:58pm
424B3
ksiiubz
14 Jun 21
Prospectus supplement
5:15pm